2024
Considerations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV prevention
2021
Chapter 10 Inpatient opioid use disorder treatment for the infectious disease physician
Seval N, Eaton E, Springer S. Chapter 10 Inpatient opioid use disorder treatment for the infectious disease physician. 2021, 189-221. DOI: 10.1016/b978-0-323-68328-9.00010-2.Peer-Reviewed Original ResearchOpioid use disorderInfectious disease physiciansDisease physiciansOpioid use disorder treatmentInitiation of medicationOpioid-related conditionsUse disorder treatmentEvidence-based treatmentsPatient-centered conceptsID consultationTreatment interruptionAcute painUse disordersOUD managementDisorder treatmentInfectionTreatmentPhysiciansCareMedicationsPainBuprenorphineNaltrexoneMethadoneDiagnosis